Prospective Asian Multicenter Prostate Cancer Focal Therapy Study (ProAMFocal)

Launched by SINGAPORE GENERAL HOSPITAL · Jul 5, 2024

Keywords

ClinConnect Summary

The ProAMFocal trial is a study looking at how effective focal therapy is for treating prostate cancer in men across Asia. Focal therapy is a treatment that targets only the cancerous part of the prostate, rather than the whole organ. This study aims to gather information from various hospitals to better understand this approach and how it works for different patients.

To be eligible for this trial, participants must be adult men diagnosed with a specific type of prostate cancer called adenocarcinoma, with a maximum Gleason score of 4+4, which indicates a certain level of aggressiveness. They should have a limited cancer volume and a PSA level (a blood marker for prostate cancer) below 15 ng/dl. Participants can expect to be monitored during their treatment and follow-up care, helping researchers learn more about the effectiveness and safety of focal therapy for prostate cancer. It's important to note that if the cancer has spread beyond the prostate, they may not qualify, but if there's just some contact with the prostate's outer layer, they might still be included.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Prostate Adenocarcinoma
• • Maximum Gleason score 4+4
• • Maximum cancer volume 1.5 ml (up to 2 lesions) or 3 ml (single lesion)
• • Maximum Prostate Specific Antigen (PSA) level 15 ng/dl
• • Maximum clinical stage T2c
• • American Society of Anesthesiologist Criteria 2 or less
• Exclusion Criteria:
• • Extra-prostatic Extension on multi parametric magnetic resonance imaging (mpMRI); capsular contact is permitted